Home » Topics » Regulatory » EMA

EMA
RSS

CHMP supports approval of Orkambi and expansion of Kalydeco indications

Sep. 28, 2015

Hemophilia A therapy Elocta recommended for E.U. approval

Sep. 28, 2015

EMA CHMP recommends approval of dabigatran reversal agent idarucizumab

Sep. 28, 2015

EMA CHMP grants accelerated assessment of Janssen's daratumumab for MM

Sep. 25, 2015

EMA recommends approval of mepolizumab for severe refractory eosinophilic asthma

Sep. 25, 2015

EMA committee recommends European approval of Entresto

Sep. 25, 2015

EMA grants orphan drug designation to Stemline's SL-401 for AML

Sep. 14, 2015

European ADAPT SMART initiative launched to improve efficiency in drug development

Sep. 8, 2015

Audentes Therapeutics' AT-001 receives orphan drug designation

Aug. 27, 2015

Filings accepted for afatinib as second-line treatment for squamous cell carcinoma of the lung

Aug. 25, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...